focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFUL.L Regulatory News (FUL)

  • There is currently no data for FUL

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI)

22 May 2023 09:51

RNS Number : 1928A
Singer Capital Markets Sec Ltd
22 May 2023
 

FORM 8.5 (EPT/RI)

 

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Singer Capital Markets Securities Ltd

 

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

The Fulham Shore PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

The Fulham Shore PLC

(d) Date dealing undertaken:

19 May 2023

(e) In addition to the company in 1(b) above, is the exempt principal trader making disclosures in respect of any other party to this offer?

If it is a cash offer or possible cash offer, state "N/A"

NO

If YES, specify which:

 

 

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchases/ sales

 

Total number of securities

Highest price per unit paid/received

Lowest price per unit paid/received

 

ORD 0.5P

 

 

Purchase

 

148,896

 

13.921p

 

13.921p

 

ORD 0.5P

 

 

Sale

 

250,000

 

14p

 

14p

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

Date of disclosure:

22 May 2023

Contact name:

Jennifer Bentick

Telephone number:

020 7496 3055

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service. 

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
FERUUVWRORUVURR
Date   Source Headline
29th Apr 20101:03 pmRNSForm 8.3 - [Fulcrum Pharma plc]
29th Apr 201011:48 amRNSForm 8.5 (EPT/RI)
29th Apr 20107:00 amRNSPosting of Offer Document
28th Apr 20107:00 amRNSHalf Yearly Report
28th Apr 20107:00 amRNSOffer by Gold Medal Acquisitions UK Limited
26th Apr 20104:41 pmRNSForm 8.3 - Fulcrum Pharma Plc
26th Apr 20108:21 amRNSForm 8.5 (EPT/RI)
20th Apr 201011:36 amRNSForm 8.5 (EPT/RI)
20th Apr 201010:27 amRNSForm 8.3 - FULCRUM PHARMA PLC
12th Apr 20108:45 amRNSEPT Disclosure
7th Apr 201010:32 amRNSEPT Disclosure
6th Apr 201010:03 amRNSEPT Disclosure
1st Apr 201010:46 amRNSEPT Disclosure
31st Mar 20108:37 amRNSEPT Disclosure
29th Mar 201010:01 amRNSEPT Disclosure
25th Mar 201012:39 pmRNSRule 8.3- Fulcrum Pharma
25th Mar 20109:35 amRNSEPT Disclosure
24th Mar 20109:35 amRNSEPT Disclosure
23rd Mar 201011:51 amRNSEPT Disclosure
17th Mar 20109:56 amRNSEPT Disclosure
11th Mar 201010:38 amRNSEPT Disclosure
10th Mar 201010:16 amRNSEPT Disclosure
19th Feb 201011:13 amRNSEPT Disclosure
18th Feb 201011:14 amRNSEPT Disclosure
9th Feb 20109:28 amRNSEPT Disclosure
5th Feb 20109:09 amRNSEPT Disclosure
3rd Feb 20108:38 amRNSEPT Disclosure
13th Jan 201010:05 amRNSRule 8.3- Fulcrum Pharma PLC
13th Jan 201010:04 amRNSEPT Disclosure
7th Jan 201010:37 amRNSEPT Disclosure
5th Jan 20109:21 amRNSEPT Disclosure
22nd Dec 200911:31 amRNSResult of AGM
19th Nov 200911:12 amRNSStatement re share price movement
12th Nov 20097:00 amRNSFinal Results
16th Jul 20094:31 pmRNSDirectors' Dealings / issue of options
8th Jun 20097:00 amRNSDirectorate Change
14th May 20097:00 amRNSHalf Yearly Report
23rd Dec 200812:34 pmRNSResult of AGM
24th Nov 20087:00 amRNSDirector/PDMR Shareholding
14th Nov 20087:00 amRNSCollaboration with Quantum Solutions
12th Nov 20087:00 amRNSFinal Results
26th Sep 20087:00 amRNSBoard Changes
12th Sep 20085:28 pmRNSDirector/PDMR Shareholding-Replacement
12th Sep 200811:40 amRNSDirector/PDMR Shareholding
2nd Sep 20087:00 amRNSAppointment of Director
5th Jun 20083:59 pmRNSDirector/PDMR Shareholding
22nd May 20087:00 amRNSInterim Results
10th Mar 20087:00 amRNSAppointment of new CEO
1st Feb 20084:10 pmRNSResult of AGM
22nd Jan 20087:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.